Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 16624552

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Eur J Cancer
Publication date
2006 May
First author
Debiec-Rychter M

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Debiec-Rychter M
      type
      Author
    2. name
      Sciot R
      type
      Author
    3. name
      Le Cesne A
      type
      Author
    4. name
      Schlemmer M
      type
      Author
    5. name
      Hohenberger P
      type
      Author
    6. name
      van Oosterom AT
      type
      Author
    7. name
      Blay JY
      type
      Author
    8. name
      Leyvraz S
      type
      Author
    9. name
      Stul M
      type
      Author
    10. name
      Casali PG
      type
      Author
    11. name
      Zalcberg J
      type
      Author
    12. name
      Verweij J
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Debiec-Rychter M
      type
      Author
    2. name
      Sciot R
      type
      Author
    3. name
      Le Cesne A
      type
      Author
    4. name
      Schlemmer M
      type
      Author
    5. name
      Hohenberger P
      type
      Author
    6. name
      van Oosterom AT
      type
      Author
    7. name
      Blay JY
      type
      Author
    8. name
      Leyvraz S
      type
      Author
    9. name
      Stul M
      type
      Author
    10. name
      Casali PG
      type
      Author
    11. name
      Zalcberg J
      type
      Author
    12. name
      Verweij J
      type
      Author
    bibliography ids
    1. nci-bib-76a53a8cadef0312b73f3214
    book metadata
    content sha256
    3dfd18b1b1a6d217f73b8b0a6fbe8b82b4e8cbee3a18190cd7587af78f7300b4
    document type
    citation
    dois
    1. 10.1016/j.ejca.2006.01.030
    electronic publication date
    display
    2006 Apr 18
    precision
    day
    year
    2006
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:16624552
    immutable id
    pubmed:16624552@3dfd18b1b1a6d217f73b8b0a6fbe8b82b4e8cbee3a18190cd7587af78f7300b4
    journal
    abbreviation
    Eur J Cancer
    issn electronic
    Source null
    issn print
    0959-8049
    issue
    8
    name
    European journal of cancer (Oxford, England : 1990)
    nlm unique id
    9005373
    pages
    1093-103
    volume
    42
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      16624552
      provenance
      batch id
      19fb2de9a00882c94e86
      provider
      NCBI PubMed ESummary
      record sha256
      7ab11745bb8174f0aec3c60eb89c627bd6e89b9f53a5e214ce580830b6418f00
      response sha256
      4c446464d8fd06bff771a2bb5f3529ef4abe372e3c19f6fb7223068d839a263d
      retrieved at
      2026-09-09T23:46:06.810486+00:00
      publication date
      display
      2006 May
      precision
      month
      year
      2006
      publication types
      1. Clinical Trial, Phase III
      2. Journal Article
      3. Randomized Controlled Trial
      4. Research Support, Non-U.S. Gov't
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/16624552/
      title
      KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.

      Preserved source evidence · Not medical advice